Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Cerus Corporation

Market Cap 519M 450M 415M 389M 727M 49.69B 742M 4.95B 1.92B 23.95B 1.95B 1.91B 83.28B P/E Ratio 2026 *
-77.7x
P/E Ratio 2027 * -778x
Enterprise Value 519M 450M 415M 389M 727M 49.69B 742M 4.95B 1.92B 23.95B 1.95B 1.91B 83.28B EV / Sales 2026 *
2.18x
EV / Sales 2027 * 2x
Free-Float
96.59%
Yield 2026 *
-
Yield 2027 * -
1 day+3.09%
1 week-7.17%
Current month-14.80%
1 month+2.78%
3 months+44.69%
6 months+20.47%
Current year+25.73%
1 week 2.46
Extreme 2.46
2.81
1 month 2.33
Extreme 2.33
3.13
Current year 1.62
Extreme 1.62
3.15
1 year 1.15
Extreme 1.15
3.15
3 years 1.12
Extreme 1.12
3.15
5 years 1.12
Extreme 1.12
8.06
10 years 1.12
Extreme 1.12
8.87
Manager TitleAgeSince
Chief Executive Officer 59 2011-04-20
Chief Tech/Sci/R&D Officer 82 2015-06-30
Director of Finance/CFO 54 2009-05-03
Director TitleAgeSince
Chairman 59 2025-06-19
Director/Board Member 72 2014-03-23
Director/Board Member 66 2018-10-08
Date Insider Type Main position Quantity % Market Cap.
06-01Free

Director

60,000 0.0299%
06-01Free

Director

60,000 0.0299%
06-01Free

Director

60,000 0.0299%
Change 5-day change 1-year change 3-year change Capi.($)
+2.90%-7.17%+82.39%+2.78% 519M
+0.92%+1.47%-19.80%+8.91% 117B
-0.04%-0.52%+2.84%-3.71% 12.86B
-0.45%+2.11%+25.33%+84.50% 7.29B
-0.74%-5.28%-47.72%-69.62% 4.12B
-0.82%+3.46%+8.80%+30.33% 2.49B
+2.98%+4.59%-21.26%-19.19% 1.7B
-0.70%-7.93%+1.93%-12.89% 1.63B
+13.14%+0.48%+191.03%+132.83% 1.49B
Average +1.97%-1.41%+24.84%+17.10% 16.59B
Weighted average by Cap. +0.87%+1.07%-13.26%+10.36%

Financials

2026 *2027 *
Net sales 238M 207M 190M 178M 333M 22.8B 340M 2.27B 880M 10.99B 894M 875M 38.21B 260M 225M 208M 195M 364M 24.88B 371M 2.48B 960M 11.99B 975M 954M 41.7B
Net income -6.24M -5.41M -4.99M -4.68M -8.74M -597M -8.92M -59.52M -23.04M -288M -23.42M -22.91M -1B -479K -416K -383K -359K -671K -45.9M -685K -4.57M -1.77M -22.12M -1.8M -1.76M -76.92M
Net Debt - -
Logo Cerus Corporation
Cerus Corporation is a biomedical products company. The Company is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on its proprietary technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives: platelets, plasma, red blood cells and to produce INTERCEPT Fibrinogen Complex (IFC), and pathogen reduced plasma, cryoprecipitate reduced. The INTERCEPT Blood System for Cryoprecipitation uses its plasma system to produce IFC for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. In addition, the INTERCEPT Blood System for Cryoprecipitation is used to produce pathogen reduced plasma, cryoprecipitate reduced.
Employees
268
Date Price Change Volume
26-06-12 2.700 $ +4.25% 117,707
26-06-11 2.590 $ +1.17% 3,859,805
26-06-10 2.560 $ -0.78% 1,840,934
26-06-09 2.580 $ -0.77% 2,240,904
26-06-08 2.600 $ -4.06% 1,672,954
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
2.590USD
Average target price
4.667USD
Spread / Average Target
+80.18%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CERS Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!